These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2239480)

  • 1. Longitudinal study of effects of early levodopa treatment on disability and mortality in Parkinson's disease.
    Diamond SG; Markham CH
    Adv Neurol; 1990; 53():399-403. PubMed ID: 2239480
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 6. 'Drug holidays' in the treatment of Parkinson's disease. A brief review.
    Friedman JH
    Arch Intern Med; 1985 May; 145(5):913-5. PubMed ID: 3888135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Which drug to use for the initiation of treatment for early Parkinson's disease].
    Marttila R
    Duodecim; 2004; 120(5):587-90. PubMed ID: 15060995
    [No Abstract]   [Full Text] [Related]  

  • 8. Parkinson's disease: progression and mortality.
    Hoehn MM
    Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-lasting drug holiday in Parkinson's disease.
    Bermejo F; Calandre L; Molina JA; Martinez P; De Yebenes JG
    Adv Neurol; 1987; 45():503-6. PubMed ID: 3103392
    [No Abstract]   [Full Text] [Related]  

  • 11. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D; Friedman A
    Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of early dopa treatment in Parkinson's disease.
    Markham CH; Diamond SG
    Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement.
    Lucetti C; Gambaccini G; Del Dotto P; Ceravolo R; Logi C; Rossi G; Murri L; Bonuccelli U
    Parkinsonism Relat Disord; 2006 Jun; 12(5):279-83. PubMed ID: 16549382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of levodopa on progression of Parkinson's disease.
    Webster DD; Mortimer JA; Kuskowski MA
    Adv Neurol; 1987; 45():473-6. PubMed ID: 3103390
    [No Abstract]   [Full Text] [Related]  

  • 18. Parkinsonism treated with levodopa: progression and mortality.
    Maier Hoehn MM
    J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Drug holiday" in Parkinson's disease.
    Kenny A; Murrin LC; Pfeiffer RF
    Nebr Med J; 1987 May; 72(5):149-53. PubMed ID: 3587443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.